Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’
Reads0
Chats0
TLDR
This data indicates that directorship of Dermatology Unit at the University of Naples Federico II is likely to have an important role in the development of regenerative medicine and in particular in the treatment of acne.Abstract:
Gabriella Fabbrocini and Fabrizio Martora Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy E-mail: angeloruggiero1993@libero.it Conflict of interest: the authors declare that they have no conflicts of interest. Funding: none. Ethics statement. Ethics approval and informed consent not applicable. Data availability: not applicable. Accepted for publication 30 May 2022read more
Citations
More filters
Journal ArticleDOI
Efficacy of Hydrogen Purification and Cosmetic Acids in the Treatment of Acne Vulgaris: A Preliminary Report
Karolina Chilicka,Monika Rusztowicz,Aleksandra M. Rogowska,Renata Szyguła,Binnaz Asanova,Danuta Nowicka +5 more
TL;DR: The skin eruptions in patients were reduced and the authors observed lower amounts of sebum on the surface of the epidermis, and an improvement in skin hydration, in group B, the results were better than in group A.
Journal ArticleDOI
Management of patients with hidradenitis suppurativa during COVID‐19 vaccination: An experience from Southern Italy
TL;DR: This study suggests that biologic treatments for psoriasis, particularly anti-IL-17 agents, sustain their beneficial results in the long run even during COVID-19 infection, given that SARS-CoV-2 seems to initiate an IL-17-enriched response.
Journal ArticleDOI
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
TL;DR: Guselkumab safety and efficacy profiles in psoriasis have been showed by VOYAGE (1 and 2) trials as discussed by the authors , but the long-term real-life data about guselkumaab are still poor.
Journal ArticleDOI
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
TL;DR: The efficacy and safety of guselkumab in daily clinical practice up to 3 years are confirmed, suggesting this drug as an effective treatment option in psoriasis long-term management.
Journal ArticleDOI
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
TL;DR: In this article , the authors describe the role of teledermatology during the COVID-19 pandemic to analyze main strengths and limitations of this tool, as well as to provide future perspectives in clinical applications.
References
More filters
Journal ArticleDOI
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Alexa B. Kimball,Martin M. Okun,David A. Williams,Alice B. Gottlieb,Kim A. Papp,Christos C. Zouboulis,April W. Armstrong,Francisco A. Kerdel,Michael H. Gold,Seth B Forman,Neil J. Korman,Evangelos J. Giamarellos-Bourboulis,Jeffrey J. Crowley,Charles Lynde,Ziad Reguiai,Errol-Prospero Prens,Eihab Alwawi,Nael M. Mostafa,Brett Pinsky,Murali Sundaram,Yihua Gu,Dawn M. Carlson,Gregor B.E. Jemec +22 more
TL;DR: Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar in the study groups.
Journal ArticleDOI
Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa
Christos C. Zouboulis,Hendrik Hansen,Raffaele Dante Caposiena Caro,Giovanni Damiani,Isabelle Delorme,José C. Pascual,Ziad Reguiai,Anastasia Trigoni,Eva Vilarrasa,Fernando Alfageme Roldán +9 more
TL;DR: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.), which significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index.
Journal ArticleDOI
Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.
Matteo Megna,Angelo Ruggiero,Adriana Di Guida,Angela Patrì,Gabriella Fabbrocini,Claudio Marasca +5 more
TL;DR: A 50-year-old Caucasian man was admitted at an outpatient clinic in September 2019 presenting a severe plaque psoriasis and HS, with a chronic remitting course and a severe exacerbation of cutaneous lesions and articular pain at knees when he addressed the clinic.
Journal ArticleDOI
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
Angelo Ruggiero,Fabrizio Martora,V. Picone,Laura E. Marano,Gabriella Fabbrocini,Claudio Marasca +5 more
TL;DR: All current data on paradoxical HS triggered by biological drugs is analyzed and follicular occlusion followed by follicular rupture has been shown to be crucial to HS development, leading to immune response activation, and resulting in typical clinical HS lesions.
Journal ArticleDOI
Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
TL;DR: Marasca et al. as mentioned in this paper described a case series of 5 patients, 2 men and 3 women, with a worsening of HS following COVID-19 vaccination, each patient was staged according to the International Hidradenitis Suppurativa Severity Score System.
Related Papers (5)
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Viola Harde,Ulrich Mrowietz +1 more